The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of first-line nab-paclitaxel/carboplatin versus gemcitabine/carboplatin in advanced squamous cell carcinoma of the lung (CTONG1002).
Jinji Yang
No relevant relationships to disclose
Cheng Huang
No relevant relationships to disclose
Yong Song
No relevant relationships to disclose
Ying Cheng
No relevant relationships to disclose
Gongyan Chen
No relevant relationships to disclose
Hong-Hong Yan
No relevant relationships to disclose
Qing Zhou
No relevant relationships to disclose
Huajun Chen
No relevant relationships to disclose
Xiao-song Ben
No relevant relationships to disclose
Yi-Long Wu
No relevant relationships to disclose